Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
MSCTrail Therapeutics
London, United Kingdom
- Ownership
- Private
- Development stage
- Other
01
Overview
MSCTrail Therapeutics was created to develop MSCTRAIL, an allogeneic umbilical cord-derived mesenchymal stromal cell therapy engineered to express TRAIL, being tested in the TACTICAL first-in-human phase I/II trial in metastatic lung adenocarcinoma in combination with cisplatin, pemetrexed and/or pembrolizumab; preclinical work demonstrated selective induction of apoptosis in lung cancer models and feasible PET-CT tracking of radiolabelled cells, while the clinical program (NCT03298763) is ongoing, with no published phase II efficacy readout yet.[2][3][4]
- Therapeutic areas
- Oncology
- Modalities
- Cell therapyGene therapyStem cell therapyBiologic
- Industry
- Biotech
02
Partnerships
UCL Business
Beyond the preview
Go deeper on MSCTrail Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MSCTrail Therapeutics.